NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI
A legfontosabb adatok
- Ki végzi
- Cell Therapy LLC
- Hol
- Chicago (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- Korai 1. fázis
- Résztvevők
- 8 fő, tervezett
- Kezdés
- 2026. szept.
- Várható befejezés
- 2027. szept.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Human allogeneic, culture expanded, UC-MSC
- A regiszteradat frissítve
- 2026. július 31.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a spinal cord injury caused by a blunt trauma within the last 10 years. It tests the safety of CE-1 donor umbilical cord stem cells injected into the spinal fluid.
- Életkor
- 18 years and older
- Nem
- Male and female
- A betegség stádiuma
- Traumatic, blunt (non-penetrating), not degenerative spinal cord injury below the C2 level, confirmed by MRI. Complete (AIS grade A) or incomplete (AIS grade B, C or D). Injury within 10 years; both recent and chronic injuries can join.
- Korábbi kezelés
- People who ever had MSC, gene or exosome therapy cannot join. Steroids used early after the injury are allowed, but must have stopped at least 14 days before the injection. No anti-rheumatic medicines (such as methotrexate) within 3 months.
- Biomarker vagy leletérték
- Negative blood tests for HIV, VDRL (syphilis), Hepatitis B and C. Normal creatinine, ALT, AST, total bilirubin and NT-ProBNP. Platelets 100,000 /μL or higher and INR 1.5 or lower.
A részvétel fő kizáró okai
- Pregnant, nursing, or planning pregnancy during the study
- Long-term immune-suppressing treatment or ongoing infection such as tuberculosis, HIV, hepatitis or syphilis
- Serious heart, brain, kidney, liver or hormone disease, or bleeding or blood disorders
- Past cancer, except localized skin cancers
- Brain injury, schizophrenia, bipolar disorder, untreated depression, or alcohol or drug abuse
A regiszter feltételei, szó szerint
Mind a 37 feltétel megnézéseKevesebb
Ki vehet részt
- Once the voluntary nature of the study is explained in detail, the participant must be willing to provide written informed consent and complete HIPAA documentation before conducting any study-related procedure. A signed written informed consent and ability to comply with the study protocol according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and local regulations is required
- Male or female aged 18 years and older at the time of enrollment
- Females of childbearing potential must have a negative pregnancy test prior to receiving the study drug and will agree to use adequate contraception (hormonal/barrier method or abstinence) from the time of screening to a period of 1 year following completion of the drug treatment cycle. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than two years. If the urine pregnancy test is positive, the study drug will not be administered, and the result will be confirmed by a serum β-hCG test. β-hCG tests will be performed at a central clinical laboratory, whereas urine pregnancy tests will be performed by qualified personnel using a kit
- Females becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcomes. Any serious adverse events (SAE) associated with pregnancy will be recorded
- SCI categorized as either complete (AIS grade A) or incomplete (AIS grade B, C or D) at the time of recruitment
- Injuries located below the C2 level confirmed by MR imaging
- SCI must be traumatic, blunt/non-penetrating in nature, and not degenerative
- Full understanding of the requirements of the study and willingness to comply with the treatment plan, laboratory tests, diagnostic imaging, complete physical and neurologic examination, and follow-up visits and assessments
- Full understanding of the requirements of their rehabilitation program prescribed by physical and occupational therapists
- Injury within 10 years before enrollment or screening period. Both acute and chronic SCI patients may be enrolled. Chronic SCI is defined as at least one year post-injury with stabilized neurological function
- The participant must be able to tolerate intrathecal injections
- The participant must have negative serology for HIV, VDRL, Hepatitis B and C
- Adequate vital organ function defined by normal laboratory values for creatinine, ALT, AST, total bilirubin, NT-ProBNP. If these labs are out of range, they must be reviewed by PI and confirmed. Rescreening can be done after treatment and retesting
- Blood platelets count equal to or higher than 100,000 /μL and INR level equal to or less than 1.5 must be encountered
Ki nem vehet részt
- History of receiving MSC, gene or exosome therapy for any indications
- On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including chronic use of systemic steroids/corticosteroids. Use of steroids/corticosteroids in the acute SCI phase is permissible but the participant must have been off steroids for at least 14 days prior to the first injection and cannot take steroids for at least one month after injection
- Taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within 3 months prior to study enrollment
- Participation in a study of an experimental drug or medical device within 3 months of study enrollment
- Participants with untreated baseline depression, diagnosed by the Beck Depression Inventory, past medical history, and baseline assessment conducted by a psychologist or a psychiatrist. Participants with depression or anxiety disorders who are in remission or receiving treatment can be enrolled in the study
- History of intra-spinal infection
- History of superficial infection in the index spinal level within 6 months of enrollment
- Evidence of current superficial infection affecting the index spinal level at the time of enrollment
- Ongoing infectious disease, including but not limited to tuberculosis, HIV, hepatitis, and syphilis
- Clinically significant cardiovascular (e.g., history of myocardial infarction, congestive heart failure or uncontrolled hypertension > 90 mmHg diastolic and/or 180 mmHg systolic), neurological (e.g., stroke, TIA) renal, hepatic or endocrine disease (e.g., diabetes, osteoporosis)
- History of malignancy including melanoma except for localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline). Any other malignancy will not be allowed. Provided they have not demonstrated clinical signs or symptoms of infection and have not required treatment, participants with large granular lymphocytic leukemia, upon consultation with their Hematologist/Oncologist, may be considered but should undergo additional testing at screening
- History of blood dyscrasia, including but not limited to anemia, thrombocytopenia, and monoclonal gammopathy
- History or presence of brain injury, hydrocephalus, meningitis, cerebral palsy, altered consciousness, signs/symptoms of neurodegenerative disorders (e.g., stroke, amyotrophic lateral sclerosis, multiple sclerosis, etc.), based on medical history and at the discretion of the investigator
- Known allergy to local anesthetics of other components of the study drug
- History of or current evidence of alcohol or drug abuse or dependence, recreational use of an illicit drug or prescription medications, or use of medical marijuana within 28 days of study entry
- Diagnosis of schizophrenia or bipolar disorder
- Any severe condition pre-existing before or after traumatic SCI at the discretion of the Principal Investigator (PI)
- History of bleeding disorders and actual levels of blood platelet lower than 100,000/μL and/or INR equal to or higher than 1.5
- Pregnant or nursing, or planning on becoming pregnant during the study period
- SCI initially classified as AIS grade E at the time of injury
- SCI located above C2 level confirmed by magnetic resonance imaging (MRI)
- Fever, defined as temperature above 99ºF/37.2ºC or mental confusion at the time of IPA
- Any contraindication to MRI scan according to MRI guidelines, or unwillingness to undergo MRI procedures
Helyszínek itt: Egyesült Államok
- The University Of ChicagoChicago, Egyesült ÁllamokContact: Senior Program CoordinatorToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the safety and tolerability of intrathecal administration of CE-1 at a weight-based dose (cells/kg BW), capped at a maximum total dose of 1×10⁸ cells in 10 mL, with administered volume calculated using M = 0.167 mL/kg BW.
A teljes eredeti leírásKevesebb
Study details include:
The overall study duration will be up to three years. The primary endpoint will be assessed at 6 months following investigational product administration. An additional secondary endpoint will be assessed at 12 months in the form of a phone call.
Study visits therefore consist of one interventional visit, an evaluation visit within two weeks post-injection, a primary endpoint follow-up visit at 6 months, and a secondary endpoint follow-up phone call at 12-months.
A vizsgálat csoportja
- CE-1A vizsgált kezelés
Allogenic Umbilical Cord-Derived Mesenchymal Stem Cells
Kezelés: Human allogeneic, culture expanded, UC-MSC
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single-Arm and Open Labeled Clinical Study of CE1 (Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells, or UC-MSC) in Traumatic Spinal Cord Injury Patients Within Ten Years of Injury
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 31.